
Daiichi Sankyo is laying off 16% of its staff at its US commercial headquarters as the company braces itself for …

Daiichi-Sankyo will pay the US government and state Medicaid programmes $39 million to resolve claims that it violated the False …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

